Show simple item record

dc.contributor.authorPaz-Ares, L. G.en
dc.contributor.authorFelip, E.en
dc.contributor.authorAhn, M. J.en
dc.contributor.authorBlackhall, Fiona Hen
dc.contributor.authorBorghaei, H.en
dc.contributor.authorCho, B. C.en
dc.contributor.authorJohnson, M. L.en
dc.contributor.authorRamalingam, S. S.en
dc.contributor.authorReck, M.en
dc.contributor.authorZhang, A.en
dc.contributor.authorJu, C. H.en
dc.contributor.authorMinocha, M.en
dc.contributor.authorMukherjee, S.en
dc.contributor.authorSuri, G.en
dc.contributor.authorJandial, D.en
dc.contributor.authorBebb, D. G.en
dc.date.accessioned2023-10-25T08:48:38Z
dc.date.available2023-10-25T08:48:38Z
dc.date.issued2023en
dc.identifier.citationPaz-Ares LG, Felip E, Ahn MJ, Blackhall FH, Borghaei H, Cho BC, et al. Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304). Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005482.en
dc.identifier.doi10.1200/JCO.2023.41.16_suppl.TPS8611en
dc.identifier.urihttp://hdl.handle.net/10541/626662
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2023.41.16_suppl.TPS8611en
dc.titleRandomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentHospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit, Ciberonc and Universidad Complutense, Madrid, Spainen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record